Pangyo, Gyeonggi Province, Korea - SK Biopharmaceuticals today released the '2022 SK Biopharmaceuticals Sustainability Report' to highlight key achievements and define its goals in environmental, social and governance (ESG). The report includes the company's vision toward 'A New Decade' to strengthen its capabilities and expand its business.

SK Biopharmaceuticals has taken significant steps to promote sustainability practices, led by its Board of Directors. The 2022 report highlights progress that has been made as well as a key action plans to be implemented in the five main sustainability areas: creation of healthcare values; minimized environmental impact; sustainable partnership; competent and happy employees; transparent and ethical operation.

'SK Biopharmaceuticals has led the creation of social and economic value even facing the COVID-19 pandemic, increasing its presence in the top 4 global markets including the U.S., Europe, Japan and China,' said Jeong-Woo Cho, President & CEO of the company. 'We remain committed to improving social and environmental conditions both in the global biopharmaceuticals industry and in our communities while strengthening ESG management to ensure that we can continue to provide safe high-quality medicines in the global market.'

With the expansion of cenobamate, its anti-seizure medication, into key markets including the United States, SK Biopharmaceuticals created social value amounting to approximately KRW152.1 billion in the 'creation of healthcare values' area. By 2023, the company aims to maximize its social value with its capabilities and business competitiveness and lead global central nervous system field by providing its innovative treatments as well as expanding its medicines in markets more than two-fold compared to in 2020.

In the 'minimized environmental impact' area, SK Biopharmaceuticals sourced 54% of power from renewable energy through K-RE100 in 2021, and developed a mid and long-term plan for the ambitious 'Net Zero by 2040' initiative unveiled last year. To achieve a 33% carbon emissions reduction by 2030 and a further 66% reduction by 2035, it will build an emission inventory system by 2025, which will allow the company to implement its greenhouse gas reduction plan across the supply chain and to more directly engage in emission reduction activities beginning in 2026.

In the 'sustainable partnership' area, the company's goal is to encourage all the partners to adhere to its ESG Guidelines developed last year and to participate in its ESG risk assessment. In the 'competent and happy employees' area, SK Biopharmaceuticals will implement the unique career development system. In the 'transparent and ethical operation' area, the company will focus on minimizing the risk in anti-corruption and compliance practices and increasing stakeholders' trust.

As one of the leading global pharmaceutical companies, SK Biopharmaceuticals has been strengthening its governance system to the highest level by adopting ESG practices for its U.S. subsidiary, SK life science. In February 2022, SK Biopharmaceuticals became the first Korean biopharmaceutical company to join the Pharmaceutical Supply Chain Initiative (PSCI), a global initiative which aims to promote responsible practices across the global healthcare supply chain. The company continues to increase its commitment to ESG management, which includes preemptively responding to ESG risks in its global partnerships and working with a broader range of ESG rating organizations.

Contact:

Media

SK Biopharmaceuticals

Hyongki Park

Director of Communications

E: h.p.comm@sk.com

Jaehee Kang

Communications Manager

E: jaeheekang@sk.com

(C) 2022 Electronic News Publishing, source ENP Newswire